In Section A, members will acquire distinct doses and schedules of oral ABBV-744 tablet to detect Risk-free dosing program. Extra individuals are going to be enrolled on the identified monotherapy dosign regimen. In Segment B, individuals will get oral ruxolitinib and ABBV-744 are going to be given as "increase-on" therapy. https://martinqcnxi.popup-blog.com/31248852/not-known-details-about-brd4-inhibition-by-abbv-744-in-cancer-research-studies